Abstract
Cancer is a global health issue that impairs the life quality of patients and origins thousands of deaths annually worldwide. Six-transmembrane epithelial antigen of the prostate (STEAP1) was identified to be overexpressed in several types of cancers, namely in prostate cancer (PCa). Considering its secondary structure, associated with its location in the cell membrane, has been suggested a role in intercellular communication between tumour cells. Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target. Several strategies have been developed during the last few years for targeting STEAP1, including antibody-drug conjugates, monoclonal antibodies (mAbs), DNA vaccines and small noncoding RNAs (ncRNAs). This review presents the current knowledge about STEAP1 protein expression in human tissues, its biochemical properties and targeting strategies with the purpose to evaluate its potential as therapeutic agent for cancer.
Keywords: STEAP1, Cancer, DNA vaccines, Monoclonal antibodies, Small noncoding RNA, prostate cancer.
Current Cancer Drug Targets
Title:Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges
Volume: 18 Issue: 3
Author(s): J. Barroca-Ferreira, J.P. Pais, M.M. Santos, A.M. Goncalves, I.M. Gomes, I. Sousa, S.M. Rocha, L.A. Passarinha and C.J. Maia*
Affiliation:
- CICS-UBI- Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilha,Portugal
Keywords: STEAP1, Cancer, DNA vaccines, Monoclonal antibodies, Small noncoding RNA, prostate cancer.
Abstract: Cancer is a global health issue that impairs the life quality of patients and origins thousands of deaths annually worldwide. Six-transmembrane epithelial antigen of the prostate (STEAP1) was identified to be overexpressed in several types of cancers, namely in prostate cancer (PCa). Considering its secondary structure, associated with its location in the cell membrane, has been suggested a role in intercellular communication between tumour cells. Taking into account its high specificity and overexpression in human cancers, STEAP1 is nowadays a promising candidate to be imposed as a therapeutic target. Several strategies have been developed during the last few years for targeting STEAP1, including antibody-drug conjugates, monoclonal antibodies (mAbs), DNA vaccines and small noncoding RNAs (ncRNAs). This review presents the current knowledge about STEAP1 protein expression in human tissues, its biochemical properties and targeting strategies with the purpose to evaluate its potential as therapeutic agent for cancer.
Export Options
About this article
Cite this article as:
Barroca-Ferreira J., Pais J.P., Santos M.M., Goncalves A.M., Gomes I.M., Sousa I., Rocha S.M., Passarinha L.A. and Maia C.J.*, Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges, Current Cancer Drug Targets 2018; 18 (3) . https://dx.doi.org/10.2174/1568009617666170427103732
DOI https://dx.doi.org/10.2174/1568009617666170427103732 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Testicular Cell Junction: A Novel Target for Male Contraception
Current Medicinal Chemistry Bacteriochlorophyll a and Its Derivatives: Chemistry and Perspectives for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Do Drugs Work for ΟΑΒ Following Prostate Cancer Surgery
Current Drug Targets 6-Chloro-7-methyl-3', 4'-dimethoxyflavone – a Potent Selective COX-2 Inhibitor
Medicinal Chemistry Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry The Role of Tumor Suppressor DLC-1: Far From Clear
Anti-Cancer Agents in Medicinal Chemistry Role of Caspases, Bax and Bcl-2 in Chrysin-Induced Apoptosis in the A549 Human Lung Adenocarcinoma Epithelial Cells
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Compounds as Melatonin Agonists and Antagonists
Mini-Reviews in Medicinal Chemistry Curcumin and Liver Cancer: A Review
Current Pharmaceutical Biotechnology Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma
Current Signal Transduction Therapy Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell Apoptosis
Recent Patents on Anti-Cancer Drug Discovery Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Combining Chemotherapy with Immunotherapy in Colorectal Cancer: A Review
Clinical Cancer Drugs Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Fluorescent Molecular Imaging: Technical Progress and Current Preclinical and Clinical Applications in Urogynecologic Diseases
Current Molecular Medicine Ginsenoside Rb1 Directly Scavenges Hydroxyl Radical and Hypochlorous Acid
Current Pharmaceutical Design Nanosystems in Drug Targeting: Opportunities and Challenges
Current Nanoscience